Default Category
-
U.S. Universities and Technology Transfer
Hamermesh, Richard G.; Lerner, Josh; Andrews, PhillipCase HBS-812016-EEntrepreneurshipTechnology transfer from U.S. universities to industry has increased dramatically in the last 25 years. Reviews the history of technology transfer with particular emphasis on the Bayh-Dole Act of 1980. It then examines how universities responded to Bayh-Dole, the growth of technology transfer offices, and compares how three different universities (MIT, Stanford, and Harvard) approach technology transfer. Provides an overview of the technology tra...Starting at €8.20
-
Fairview Capital
Rogers, Steven S.; Collins, DerrickCase HBS-319050-EEntrepreneurshipFairview Capital is a pioneering alternative assets investment manager, as it is the first U.S. private equity fund of funds that focused on investing in private equity and venture capital funds managed by African-Americans and other minority investment managers. This case study focuses on Fairview's strategic decisions that ultimately led to the growth and expansion of its investment portfolio to over $3 billion.Starting at €8.20
-
Gene Patents (A)
Hamermesh, Richard G.; Kiron, David; Andrews, PhillipCase HBS-811089-EEntrepreneurshipIn March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues deal with the potential implications of Judge Sweet's decision for biotechnology entrepreneurs and investors.Starting at €8.20
-
Innovating at AT&T: Partnering to Lead the Broadband Revolution
Applegate, Lynda M.; Andrews, Phillip; Herman, KerryCase HBS-812124-EEntrepreneurshipTo maximize their effectiveness, color cases should be printed in color. In 2010, the U.S. retail market value for next-generation non-handset wirelessly-enabled devices was just over $1 billion. By 2011 it had grown 1,141% to $13.2 billion and was forecast to reach $24.7 billion in 2015. At the same time, user demand for data was surging with the popularity of mobile Internet, e-mail, and messaging, which left carriers scrambling to increase net...Starting at €8.20
-
Frank Baker: Siris Capital Group and Titan Systems
Rogers, Steven S.; Collins, DerrickCase HBS-317036-EEntrepreneurshipPrivate equity firm, Siris Capital Group must decide if they should raise their offer to take Titan Telecom private by acquiring its publicly-traded stock. Siris' decision to pay a premium for Titan must be made in the context of their unique (and somewhat complex) investment strategy that focuses on investment targets that have both mission-critical products or services that are approaching obsolescence but producing predictable cash flows, and ...Starting at €8.20
-
Corey Thomas and the IPO
Rogers, Steven S.; Collins, DerrickCase HBS-317082-EEntrepreneurshipCorey Thomas, CEO of the company Rapid7, must decide if it is the right time to take the 15-year old startup public, as it stood poised to capitalize on what appears to be the next frontier for digital technology markets - cybersecurity. In spite of positive industry trends, there are some nagging concerns that this might be a risky time in the public capital markets. The company had just completed an acquisition and he had additional concerns th...Starting at €8.20
-
Gene Patents (B)
Hamermesh, Richard G.; Andrews, PhillipCase HBS-812130-EEntrepreneurshipThe case updates events since the Court's ruling against Myriad Genetics on March 29, 2010 and should be used in conjunction with Gene Patents (A). On July 29, 2011, a US Appeals Court reversed the prior ruling against Myriad. On September 16, 2011, the first major overhaul of US Patent law in nearly 60 years was signed into law. Among other provisions, the law moved the US to a first to-file priority when granting patents, as was the practice...Starting at €5.74
-
Companion Diagnostics: Uncertainties for Approval and Reimbursement
Hamermesh, Richard G.; Selby, Norman C; Andrews, PhillipCase HBS-813037-EEntrepreneurshipThe FDA approvals of novel therapeutics were seen as signs in the personalized medicine community of real progress in the growth of personalized medicine; The FDA's approval of such drugs, along with companion diagnostics, suggested a shift in thinking and regulatory practices at the agency. Beyond the regulatory questions, many considered the reimbursement system archaic, dispersed, unpredictable, and unnecessarily time consuming. Many questione...Starting at €8.20